SERUM HOMOCYSTEINE LEVELS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Öz

-

Anahtar Kelimeler

• -

SERUM HOMOCYSTEINE LEVELS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Abstract

Aim: Non-alcoholic fatty liver disease (NAFLD) is a common disorder which causes serum liver enzyme elevation. Elevated homocysteine levels was demonstrated in fatty liver disease and chronic liver failure. However, enough data related with homocysteine levels in patients with NAFLD is not available. We aimed to find out whether there is an association between homocysteine levels and NAFLD. Methods: Twenty patients (14 men, 6 women) with NAFLD and 20 healthy adults (13 men, 7 women) enrolled in the study. Fasting blood samples were obtained and serum homocysteine levels were measured by fluorescence polarization immunoassay (FPIA) technology. Oral glucose tolerance test was performed and serum insulin, c-peptide, and lipoprotein levels were also measured. Results: The mean serum homocysteine levels (+/-SD) were 13.44±3.10 μmol/L and 11.62 ±1.34 μmol/L in NAFLD and the control group, respectively. Mean serum homocysteine level in the NAFLD group was significantly higher than in control group (p=0.015). Fasting blood glucose, insulin, total cholesterol and low density lipoprotein (LDL) cholesterol were all found higher than the control group. Conclusion: The serum homocysteine levels were significantly higher in patients with NAFLD than in control group. This may point out that high homocysteine levels may be associated with NAFLD

Keywords

• Homocysteine, non-alcoholic steatohepatitis, insulin resistance

Kaynakça

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434–8
2. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106–10
3. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74–80
4. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103– 9
5. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002;97:14-24
6. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45
7. Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocysteinemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8
8. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;18:133-8

9. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis 1998;139:197-8
10. Sanchez-Margalet V, Valle M, Ruz FJ, Gascon F, Mateo J, Goberna R. Elevated plasma total homocysteine levels in hyperinsulinemic obese subjects. J Nutr Biochem 2002;13:75-9
11. Meigs JB, Jacques PF, Selhub J, et al. Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 2001;24:1403-10
12. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1764–79 13. Torres L,
13. Garcia-Trevijano ER,
14. Rodriguez JA, et al. Induction of TIMP-1
15. expression in rat hepatic stellate cells and
16. hepatocytes: a new role for homocysteine
17. in liver fibrosis. Biochim Biophys Acta 1999;1455:12–22
18. Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhomocysteinemia in liver cirrhosis: mechanism and role in vascular and hepatic fibrosis. Hypertension 2001; 38:1217-21
19. Halsted CH, Villanueva J, Chandler CJ, et al. Ethanol feedings of micropigs alters methionine metabolism and increases hepatocellular apoptosis and proliferation. Hepatology 1996;23:497- 505
20. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450–5
21. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844–5
22. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3–10
23. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000; 75: 733–9 20. De Knegt RJ. steatohepatitis: clinical significance and pathogenesis. Scand J Gastroenterol 2001; (Suppl 234):88-92 Non-alcoholic
24. Rosolova H, Simon J, Mayer O Jr, Racek J, Dierze T, Jacobsen DW. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 2002;51: 93-8 22. Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG. Plasma total homocsyteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J Clin Endocrinol Metab 2001;86:719-23
25. Hultberg B, Berglund M, Andersson A, Frank A. Elevated plasma homocysteine in alcoholics. Alcohol Clin Exp Res 1993; 17: 687-689.
26. Lambert D, Benhayoun S, Adjalla C, et al. Alcoholic cirrhosis and cobalamin metabolism. Digestion 1997;58:64-71
27. Mudd SH, Levy HL, Skovby F. Disorders of transsulfationitors. In: Scriver CR, Beadet AL, Sly WS, and Valle D, eds. The metabolic basis for inherited diseases. New York : McGraw-Hill,1989; 693–734
28. Gaull G, Sturman JA, Schaffner F. Homocystinuria due to cystathionine synthase deficiency: enzymatic and ultrastructural studies. J Pediatr 1974; 84:381–90
29. Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001;107:1263–73
30. Bosy-Westphal A, Petersen S, Hinrichsen H, Czech N, J Muller M. Increased plasma homocysteine in liver cirrhosis. Hepatol Res 2001;20:28-38
31. Bosy-Westphal A, Ruschmeyer M, Czech N, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003;77:1269-77
32. Look MP, Riezler R, Reichel C, et al. Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at level of gamma- cystathionase? Scand J Gastroenterol 2000;35:866–72
33. Cotton F, Wautrecht JC, Lechevin V, et al. Reference intervals for plasma homocysteine by the AxSYM immunoassay after collection in fluoride tubes. Clin Chem 2003;49:315-7